Dapagliflozin for treating chronic heart failure with reduced ejection fraction – guidance (TA679)

Dapagliflozin is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction only if used as an add-on to optimised standard care outlined in the guidance. Dapagliflozin should only be started on advice from a heart failure specialist.

National Institute for Health and Care Excellence